chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Cough, Death, Diarrhoea, Dyspnoea
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Eosinophil count decreased, Eosinophil percentage decreased, Fibrin D dimer increased, Glomerular filtration rate decreased, Glucose urine absent
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Granulocyte percentage, Haematocrit decreased, Haemoglobin decreased, Hypoxia, Immature granulocyte percentage increased
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Impulse oscillometry, Inappropriate schedule of product administration, Inflammatory marker increased, Influenza A virus test negative, Influenza B virus test
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza virus test negative, Lipase normal, Lymphocyte count, Lymphocyte count normal, Lymphocyte percentage decreased
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume normal, Mean platelet volume increased, Metamyelocyte count
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Monocyte count normal, Monocyte percentage decreased, Myelocyte count, N-terminal prohormone brain natriuretic peptide increased, Nausea
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Neutrophil count, Nitrite urine absent, Normochromic anaemia, Normocytic anaemia, Platelet count
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Platelet count normal, Pleural effusion, Protein total normal, Protein urine present, Pulmonary function test increased
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Pulmonary oedema, Pulseless electrical activity, Rales, Red blood cell count decreased, Red blood cell nucleated morphology
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate, Red blood cells urine positive, Red cell distribution width normal, Respiratory syncytial virus test negative, SARS-CoV-2 test positive
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Scan normal, Specific gravity urine normal, Tachypnoea, Troponin I increased, Troponin increased
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Urinary sediment, Urine abnormality, Urine analysis abnormal, Urine ketone body present, Urine leukocyte esterase
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Urobilinogen urine, White blood cell count increased, pH urine normal
Clinical narrative: Received 2nd vaccination dose 1/31/2021, Pfizer, EL898, IM R deltoid. No booster. 76 yo F with hypertension, hyperlipidemia, diabetes, and peripheral vascular disease presented to ED on 2/11 with dyspnea. Per history, patient had two days of symptoms (shortness of breath, weakness, nausea, and diarrhea) and reproted that "feels like i want to cough but can't". Of note, patient received first dose of COVID vaccine on 1/5/21 and second dose on 1/31, and thus at time of presentation was 11 days post-dose #2. On arrival to ED, found to be significantly hypoxic with SpO2 81% on RA and improved to 95% on 2L. Lung exam notable for tachypnea, with bilateral rales and with displaced PMI. CXR notable for cardiomegaly, diffuse pulmonary edema, right worse than left with suspected pleural effusion. Labs notable for elevated WBC to 16.5 with neutrophilic predmoninance (94%), lactate 2.3, new AKI (Cr 2.6 up from b/l < 2.0), acidosis, miledly elevated Trop and elevated BNP. EKG did not new RBBB. Primary concern was for volume overload in setting of new congestive heart failure as evidenced by BNP, cardiomegaly, pulm edema, and elevated BPs alogn with cardiorenal syndrome (AKI). Inflammatory and pulmonary markers significnatlly elevated as well though - CRP 389, LDH 2366, and DiDimer 20.03. She was transferred to a higher level of care.   At the Hospital on D#2, she had worsening hypoxia, up to 10L O2 with worsening AKI (2.9) and rising WBC. Given elevated DDimer, pt underwent Nuc Med study and PE was ruled out. Early in the morning of 2/13 (D5 and 2nd day at Hospital) patient PEA arrested with subsequent ROSC but recurrent arrests and passed early in morning of 2/13.   Patient died of these conditions after acquirring COVID 11 days after her 2nd dose of Pfizer vaccine.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling
Clinical narrative: Pain and minor swelling at the injection site; Pain and minor swelling at the injection site; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 16Mar2021 14:30 (Lot number: EL3247) at the age of 54 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: SERTRALINE; LIPITOR. Vaccination history included: Bnt162b2 (1st dose, Lot: EL3247, left arm, Time: 13:45), administration date: 25Feb2021, for Covid-19 immunization. The following information was reported: VACCINATION SITE SWELLING (non-serious) with onset 16Mar2021 17:00, outcome "recovering", VACCINATION SITE PAIN (non-serious) with onset 16Mar2021, outcome "recovering" and all described as "Pain and minor swelling at the injection site". Therapeutic measures were not taken as a result of vaccination site swelling, vaccination site pain.  Additional information: Patient had no allergies to medications, food or other products. At workplace clinic facility where the patient administered most recent COVID-19 vaccine. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Arrhythmia, Arthralgia, Blood test, Cardiac monitoring, Chest pain
Clinical narrative: Dizziness Lightheadness Paresthesia feet/hands/face Tinnitus Sudden Acute Hearing Loss Joint Pain Blurry Vision  Ear Fulness Testicle Pain Fatigue Brain Fog High Blood Pressure Arrhythmia Chest pain Electrical-like pain around the body Throat Swollen Loss of feeling in Legs
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram, Dizziness, Ear discomfort, Electrocardiogram, Electroencephalogram
Clinical narrative: Dizziness Lightheadness Paresthesia feet/hands/face Tinnitus Sudden Acute Hearing Loss Joint Pain Blurry Vision  Ear Fulness Testicle Pain Fatigue Brain Fog High Blood Pressure Arrhythmia Chest pain Electrical-like pain around the body Throat Swollen Loss of feeling in Legs
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Electromyogram, Fatigue, Feeling abnormal, Hypertension, Hypoaesthesia
Clinical narrative: Dizziness Lightheadness Paresthesia feet/hands/face Tinnitus Sudden Acute Hearing Loss Joint Pain Blurry Vision  Ear Fulness Testicle Pain Fatigue Brain Fog High Blood Pressure Arrhythmia Chest pain Electrical-like pain around the body Throat Swollen Loss of feeling in Legs
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Magnetic resonance imaging, Paraesthesia, Pharyngeal swelling, Sudden hearing loss, Testicular pain
Clinical narrative: Dizziness Lightheadness Paresthesia feet/hands/face Tinnitus Sudden Acute Hearing Loss Joint Pain Blurry Vision  Ear Fulness Testicle Pain Fatigue Brain Fog High Blood Pressure Arrhythmia Chest pain Electrical-like pain around the body Throat Swollen Loss of feeling in Legs
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus, Vision blurred, X-ray
Clinical narrative: Dizziness Lightheadness Paresthesia feet/hands/face Tinnitus Sudden Acute Hearing Loss Joint Pain Blurry Vision  Ear Fulness Testicle Pain Fatigue Brain Fog High Blood Pressure Arrhythmia Chest pain Electrical-like pain around the body Throat Swollen Loss of feeling in Legs
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: SARS COVID 2 PCR : positive; SARS COVID 2 PCR : positive; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 38 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 03Mar2021 10:00 (Lot number: EN6199) at the age of 37 years as dose 2, single and administered in arm left, administration date 10Feb2021 11:00 (Lot number: EL9289) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hashimotos" (unspecified if ongoing), notes: other medical history: Hashimotos; "allergies" (unspecified if ongoing), notes: other medical history: allergies; "GERD" (unspecified if ongoing); "Asthma" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Top 8 allergens plus, reaction(s): "Known allergies: Yes-top 8 allergens plus", notes: Known allergies: Yes-top 8 allergens plus. Patient receive any other vaccines within 4 weeks prior to the COVID vaccine: No. Other medications the patient received within 2 weeks of vaccination: Yes. Prior to vaccination, was the patient diagnosed with COVID-19: No. Since the vaccination, has the patient been tested for COVID-19: Yes. The following information was reported: COVID-19 (medically significant), VACCINATION FAILURE (medically significant) all with onset 30Dec2021, outcome "unknown" and all described as "SARS COVID 2 PCR : positive". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (30Dec2021) positive, notes: Nasal Swab.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Balance disorder, Gait disturbance, Hypoaesthesia, Loss of personal independence in daily activities
Clinical narrative: SARS COVID 2 PCR : positive; SARS COVID 2 PCR : positive; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 38 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 03Mar2021 10:00 (Lot number: EN6199) at the age of 37 years as dose 2, single and administered in arm left, administration date 10Feb2021 11:00 (Lot number: EL9289) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hashimotos" (unspecified if ongoing), notes: other medical history: Hashimotos; "allergies" (unspecified if ongoing), notes: other medical history: allergies; "GERD" (unspecified if ongoing); "Asthma" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Top 8 allergens plus, reaction(s): "Known allergies: Yes-top 8 allergens plus", notes: Known allergies: Yes-top 8 allergens plus. Patient receive any other vaccines within 4 weeks prior to the COVID vaccine: No. Other medications the patient received within 2 weeks of vaccination: Yes. Prior to vaccination, was the patient diagnosed with COVID-19: No. Since the vaccination, has the patient been tested for COVID-19: Yes. The following information was reported: COVID-19 (medically significant), VACCINATION FAILURE (medically significant) all with onset 30Dec2021, outcome "unknown" and all described as "SARS COVID 2 PCR : positive". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (30Dec2021) positive, notes: Nasal Swab.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Anticoagulant therapy, COVID-19, Chest X-ray abnormal, Confusional state, Lung opacity
Clinical narrative: Patient is fully vaccinated. 74-year-old female with a past medical history of diabetes type 2, GERD, morbid obesity, who presented to the hospital with altered mental status. The patient was recently discharged from the hospital to rehab.  This morning per her niece, she did not seem the same person.  She was confused, so she brought to the hospital for evaluation.vitals were T-max 97.9, heart rate 82, respiratory rate 23, blood pressure 104/63, saturation about 90, although notes from the ER they reported that she had a SpO2 85% on room air upon arrival.  She denied any headache.  No dizziness.  No blurry vision.  No difficulty swallowing or difficulty hearing.  No chest pain or shortness of breath.  No abdominal pain.  No change in urination habits or bowel movements.The patient's x-ray showed patchy bilateral airspace opacities.  DX COVID 19.  Treatment:  oxygen, IV dexamethasone, anticoagulation, IV abx, Patient was hospitalized for 17 days and then discharged.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Mental status changes
Clinical narrative: Patient is fully vaccinated. 74-year-old female with a past medical history of diabetes type 2, GERD, morbid obesity, who presented to the hospital with altered mental status. The patient was recently discharged from the hospital to rehab.  This morning per her niece, she did not seem the same person.  She was confused, so she brought to the hospital for evaluation.vitals were T-max 97.9, heart rate 82, respiratory rate 23, blood pressure 104/63, saturation about 90, although notes from the ER they reported that she had a SpO2 85% on room air upon arrival.  She denied any headache.  No dizziness.  No blurry vision.  No difficulty swallowing or difficulty hearing.  No chest pain or shortness of breath.  No abdominal pain.  No change in urination habits or bowel movements.The patient's x-ray showed patchy bilateral airspace opacities.  DX COVID 19.  Treatment:  oxygen, IV dexamethasone, anticoagulation, IV abx, Patient was hospitalized for 17 days and then discharged.
Age: 18.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Echocardiogram, Electrocardiogram, Magnetic resonance imaging heart, Myocarditis
Clinical narrative: Chest pain, hospitalized with Myocarditis/Pericarditis, released on anti inflammatory meds
Age: 18.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pericarditis
Clinical narrative: Chest pain, hospitalized with Myocarditis/Pericarditis, released on anti inflammatory meds
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Cardiac flutter, Chest X-ray, Chest pain, Electrocardiogram, Myocarditis
Clinical narrative: Booster shot: Chest pain and fluttering of heart; diagnosed with myocarditis. Patient stayed in hospital for 2 nights (December 12-15, 2021).
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Ultrasound scan
Clinical narrative: Booster shot: Chest pain and fluttering of heart; diagnosed with myocarditis. Patient stayed in hospital for 2 nights (December 12-15, 2021).
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Asthenia, COVID-19, COVID-19 pneumonia, Cough
Clinical narrative: Admitted to Hospital on 12/7/21 for cough, weakness, SOB for 4 days.  Tested Postive for COVID 19 on 12/7/21 by RT-PCR.  Diagnosis at admission included morbidly obese female with rheumatoid arthritis on methotrexate and chronic prednisone admitted for acute hypoxemic respiratory failure secondary to SARS-CoV-2 pneumonia.  Expired on 1/10/22.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Death, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: Admitted to Hospital on 12/7/21 for cough, weakness, SOB for 4 days.  Tested Postive for COVID 19 on 12/7/21 by RT-PCR.  Diagnosis at admission included morbidly obese female with rheumatoid arthritis on methotrexate and chronic prednisone admitted for acute hypoxemic respiratory failure secondary to SARS-CoV-2 pneumonia.  Expired on 1/10/22.
Age: 7.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive
Clinical narrative: Tested positive for COVID; Tested positive for COVID; second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose; second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose; cold symptoms; This is a spontaneous report received from contactable reporter(s) (Pharmacist) from medical information team.  A 7 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 10Dec2021 15:00 (Lot number: FL0007, Expiration Date: 14Jan2022) at the age of 7 years as dose 2 (tris), 0.2 ml single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (First dose: given on 26Nov2021,, lot: FD0809, expiry: 30Jan2022, dose: 0.2ml intramuscular injection in right arm.), administration date: 26Nov2021, when the patient was 7 years old, for Covid-19 immunization.  The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "Tested positive for COVID"; OFF LABEL USE (medically significant), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome "unknown" and all described as "second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose"; NASOPHARYNGITIS (non-serious), outcome "unknown", described as "cold symptoms". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: positive.  Clinical course: Patient did not receive any other additional vaccines on the same day. No follow-up attempts are possible. No further information is expected.
Age: 7.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, Inappropriate schedule of product administration, Nasopharyngitis, Off label use
Clinical narrative: Tested positive for COVID; Tested positive for COVID; second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose; second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose; cold symptoms; This is a spontaneous report received from contactable reporter(s) (Pharmacist) from medical information team.  A 7 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 10Dec2021 15:00 (Lot number: FL0007, Expiration Date: 14Jan2022) at the age of 7 years as dose 2 (tris), 0.2 ml single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (First dose: given on 26Nov2021,, lot: FD0809, expiry: 30Jan2022, dose: 0.2ml intramuscular injection in right arm.), administration date: 26Nov2021, when the patient was 7 years old, for Covid-19 immunization.  The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "Tested positive for COVID"; OFF LABEL USE (medically significant), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome "unknown" and all described as "second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose"; NASOPHARYNGITIS (non-serious), outcome "unknown", described as "cold symptoms". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: positive.  Clinical course: Patient did not receive any other additional vaccines on the same day. No follow-up attempts are possible. No further information is expected.
Age: 7.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Tested positive for COVID; Tested positive for COVID; second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose; second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose; cold symptoms; This is a spontaneous report received from contactable reporter(s) (Pharmacist) from medical information team.  A 7 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 10Dec2021 15:00 (Lot number: FL0007, Expiration Date: 14Jan2022) at the age of 7 years as dose 2 (tris), 0.2 ml single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (First dose: given on 26Nov2021,, lot: FD0809, expiry: 30Jan2022, dose: 0.2ml intramuscular injection in right arm.), administration date: 26Nov2021, when the patient was 7 years old, for Covid-19 immunization.  The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "Tested positive for COVID"; OFF LABEL USE (medically significant), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome "unknown" and all described as "second dose of the  orange cap Pfizer Covid-19 vaccine that was administered 14 days after the first dose"; NASOPHARYNGITIS (non-serious), outcome "unknown", described as "cold symptoms". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: positive.  Clinical course: Patient did not receive any other additional vaccines on the same day. No follow-up attempts are possible. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Condition aggravated, Fatigue, Feeling abnormal, Headache
Clinical narrative: Booster; one time I fainted; Headaches; extreme sensitivity to cold; continuous nausea; continuous brain fog; continuous extreme fatigue; Some vomiting; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Dec2021 13:00 (Lot number: FI8841) at the age of 70 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Osteoporosis" (unspecified if ongoing); "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies: Sulfa drugs" (unspecified if ongoing), notes: Verbatim: Known allergies: Sulfa drugs; "Known allergies: Walnuts" (unspecified if ongoing), notes: Verbatim: Known allergies: Walnuts; "Known allergies: Bee stings" (unspecified if ongoing), notes: Verbatim: Known allergies: Bee stings; "Known allergies: Insect stings" (unspecified if ongoing); "Known allergies: Dust mites" (unspecified if ongoing), notes: Verbatim: Known allergies: Dust mites; "Known allergies: Pollens" (unspecified if ongoing); "Known allergies: Cats" (unspecified if ongoing), notes: Verbatim: Known allergies: Cats; "Known allergies: Dogs" (unspecified if ongoing), notes: Verbatim: Known allergies: Dogs. Concomitant medication(s) included: VIVELLE-DOT; LOSARTAN; VITAMIN C [ASCORBIC ACID]. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0172, Location of injection: Arm Right, Vaccine Administration Time: 12:00 PM), administration date: 06May2021, when the patient was 69 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: ERB131, Location of injection: Arm Left, Vaccine Administration Time: 12:00 PM), administration date: 15Apr2021, when the patient was 69 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (medically significant), outcome "unknown", described as "Booster"; SYNCOPE (medically significant) with onset 18Dec2021 12:45, outcome "recovering", described as "one time I fainted"; HEADACHE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Headaches"; TEMPERATURE INTOLERANCE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "extreme sensitivity to cold"; NAUSEA (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous nausea"; FEELING ABNORMAL (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous brain fog"; FATIGUE (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "continuous extreme fatigue"; VOMITING (non-serious) with onset 18Dec2021 12:45, outcome "recovering", described as "Some vomiting". Therapeutic measures were not taken as a result of syncope, headache, temperature intolerance, nausea, feeling abnormal, fatigue, vomiting.